Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial
16 auth.
F. Muntoni,
E. Bertini,
G. Comi,
J. Kirschner,
A. Lusakowska,
E. Mercuri,
M. Scoto,
W. L. van der Pol,
C. Vuillerot,
A. Burdeska,
...
M. El-Khairi,
P. Fontoura,
J. Ives,
K. Gorni,
Carol Reid,
S. Fuerst-Recktenwald
|
|
4 |
2020 |
Social Media Posts